Maze Therapeutics Inc. has divulged apolipoprotein L1 (APOL1) inhibitors reported to be useful for the treatment of chronic kidney disease, focal segmental glomerulosclerosis, diabetic retinopathy, diabetic HIV-associated nephropathy, lupus nephritis, pre-eclampsia and sepsis.
Mindrank AI Co. Ltd. and Mindrank Therapeutics (Suzhou) New Drug Research & Development Co. Ltd. have identified molecular glue degraders comprising cereblon (CRBN) ligands acting as eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers reported to be useful for the treatment of cancer.
Pharmaengine Inc. and Sentinel Oncology Ltd. have synthesized Wee1-like protein kinase (Wee1) inhibitors and proteolysis targeting chimera (PROTAC) compounds reported to be useful for the treatment of cancer.
Hanyang University and Korea Institute of Science and Technology have disclosed HER2 (erbB2) inhibitors reported to be useful for the treatment of cancer.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of neurodegeneration.
Redx Pharma plc has divulged Rho kinase 1 (ROCK1) and 2 (ROCK2) inhibitors reported to be useful for the treatment of autoimmune disease, cancer, fibrosis, inflammatory and neurological disorders.
Merck Sharp & Dohme LLC has identified targeted activator of cell kill (TACK) compounds acting as Gag polyprotein (HIV-1)/protein Pol dimerization inducers reported to be useful for the treatment of HIV infection.
Shanghai Yidi Biotechnology Co. Ltd. has synthesized proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase coupled to an androgen receptor targeting moiety via a linker reported to be useful for the treatment of spinal and bulbar muscular atrophy, prostate and breast cancer.
Shenzhen Zhongge Biotechnology Co. Ltd. has disclosed tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors reported to be useful for the treatment of cancer.
Europe has more oncology startups than the U.S., but many more U.S. companies scale up to the later growth stage. Given the proven links between patent ownership and access to finance, that critical gap is in part because U.S. companies hold nearly twice as many patents as European counterparts, according to an analysis by the European Patent Office.
RSS
